Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro

Oral Diseases

Volumn 17, Issue 2, 2011, Pages 194-199

  Walter, C ^a   Pabst, A ^a   Ziebart, T ^a   Klein, M O ^a   Al Nawas, B ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Bisphosphonate; Bisphosphonate associated osteonecrosis; Fibroblast; HUVEC; Osteoblast; Osteogenic cells

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCEIN; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG POTENCY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; JAW OSTEONECROSIS; NICK END LABELING; OSTEOBLAST; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; CLODRONIC ACID; DIPHOSPHONATES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBROBLASTS; FLUORESCEINS; FLUORESCENT DYES; HUMANS; IMIDAZOLES; IN SITU NICK-END LABELING; NITROGEN; OSTEOBLASTS; UMBILICAL VEINS;

EID: 79951565764     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2010.01720.x     Document Type: Article

References (19)

1. Allen MR, Burr DB (2008). Mandible matrix necrosis in beagle dogs after 3years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66: 987-994.
2. Allen MR, Burr DB (2009). The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67: 61-70.
3. Bassett CA, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD (1969). Diphosphonates in the treatment of myositis ossificans. Lancet 2: 845.
4. Chen T, Berenson J, Vescio R et al (2002). Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42: 1228-1236.
5. Diel IJ, Bergner R, Grotz KA (2007). Adverse effects of bisphosphonates: current issues. J Support Oncol 5: 475-482.
6. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ (1997). Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358-1367.
7. Green JR, Clezardin P (2002). Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 25: S3-S9.
8. Landesberg R, Cozin M, Cremers S et al (2008). Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66: 839-847.
9. Mashiba T, Mori S, Burr DB et al (2005). The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 23(Suppl): 36-42.
10. Montazeri AH, Erskine JG, McQuaker IG (2007). Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 79: 69-71.
11. Polizzotto MN, Cousins V, Schwarer AP (2006). Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 132: 114.
12. Reid IR, Bolland MJ, Grey AB (2007). Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41: 318-320.
13. Rogers MJ, Gordon S, Benford HL et al (2000). Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88: 2961-2978.
14. Rubegni P, Fimiani M (2006). Images in clinical medicine. Bisphosphonate-associated contact stomatitis. N Engl J Med 355: e25.
15. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 67: 2-12.
16. Santini D, Vespasiani Gentilucci U, Vincenzi B et al (2003). The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14: 1468-1476.
17. Walter C, Al-Nawas B, Grotz KA et al (2008). Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54: 1066-1072.
18. Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010). Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14: 35-41. Epub 2009 Mar 18.
19. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ (2007). Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65: 1328-1331.